DVAX
NASDAQ · Biotechnology
Dynavax Technologies Corp
$15.50
+0.00 (+0.00%)
Financial Highlights (FY 2026)
Revenue
236.37M
Net Income
23.28M
Gross Margin
82.2%
Profit Margin
9.9%
Rev Growth
-14.2%
D/E Ratio
0.38
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 82.2% | 82.2% | 50.1% | 50.1% |
| Operating Margin | -1.5% | -1.3% | -27.2% | -22.2% |
| Profit Margin | 9.9% | 9.4% | -20.9% | -19.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 236.37M | 275.59M | 289.50M | 362.88M |
| Gross Profit | 194.23M | 226.45M | 144.94M | 181.68M |
| Operating Income | -3,521,941 | -3,695,635 | -78,644,913 | -80,730,074 |
| Net Income | 23.28M | 24.43M | -60,500,728 | -70,252,711 |
| Gross Margin | 82.2% | 82.2% | 50.1% | 50.1% |
| Operating Margin | -1.5% | -1.3% | -27.2% | -22.2% |
| Profit Margin | 9.9% | 9.4% | -20.9% | -19.4% |
| Rev Growth | -14.2% | -14.2% | -5.1% | -3.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 240.33M | 240.33M | 426.75M | 382.87M |
| Total Equity | 640.72M | 640.72M | 934.57M | 930.66M |
| D/E Ratio | 0.38 | 0.38 | 0.46 | 0.41 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 4.70M | 5.20M | -85,556,315 | -114,728,260 |
| Free Cash Flow | — | — | -57,246,430 | -70,359,269 |